Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
HUTCHMED (China) ( (HK:0013) ) has issued an update.
HUTCHMED announced the approval of its drug combination ORPATHYS® and TAGRISSO® by China’s National Medical Products Administration for treating lung cancer patients with MET amplification after progression on first-line EGFR inhibitor therapy. This approval, based on the SACHI Phase III trial, marks a significant advancement in lung cancer treatment, offering a chemotherapy-free, all-oral option that reduces disease progression risk by 66%. The approval also triggers a milestone payment from AstraZeneca, underscoring the strategic collaboration between the two companies to address resistance in NSCLC treatment and expand this innovative therapy’s reach in China and potentially globally.
More about HUTCHMED (China)
HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company operates primarily in China and collaborates with global pharmaceutical companies like AstraZeneca to enhance its market reach.
Find detailed analytics on 0013 stock on TipRanks’ Stock Analysis page.